Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05279027 | Zr89 + PET Companion Trial | active not recruiting | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04741997 | Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | recruiting | Early Phase 1 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05358938 | Exercise to Boost Response to Checkpoint Blockade Immunotherapy | active not recruiting | Early Phase 1 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | not yet recruiting | Early Phase 1 | 80 | Indiana UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07700121 | PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma(PICSTAT) | not yet recruiting | Early Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05498792 | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | recruiting | Early Phase 1 | 12 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07586904 | Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma. | recruiting | Early Phase 1 | 10 | Xijing HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06216938 | RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | recruiting | Early Phase 1 | 25 | Yana NajjarOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05704933 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | completed | Early Phase 1 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03276832 | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | completed | Early Phase 1 | 7 | Mayo ClinicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | active not recruiting | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05098184 | A Study of GC101 TIL in Advanced Melanoma (10hospital) | recruiting | Early Phase 1 | 50 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06472661 | FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma(Mel 70) | recruiting | Early Phase 1 | 11 | University of VirginiaOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT02652455 | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | completed | Early Phase 1 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04581382 | Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | completed | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06756295 | A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)(FAST-CR) | not yet recruiting | Early Phase 1 | 154 | Fengming KongOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT03784625 | Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012(MELRIV-1) | completed | Early Phase 1 | 10 | Centre Jean PerrinOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03893019 | MB-CART20.1 Melanoma | terminated | Early Phase 1 | 9 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | May 16, 2024 | clinicaltrials |
| NCT06212388 | Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma | not yet recruiting | Early Phase 1 | 10 | Xijing HospitalOTHER | 0 | Jan 25, 2024 | clinicaltrials |
| NCT04663126 | Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma(Tilmanocept) | terminated | Early Phase 1 | 5 | John O. PriorOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02382549 | A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib(Mel61) | terminated | Early Phase 1 | 8 | Craig L Slingluff, JrOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05961111 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03060356 | Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) | terminated | Early Phase 1 | 77 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02591654 | MRI and PET to Assess Pembrolizumab Response(MPAK) | terminated | Early Phase 1 | 6 | Columbia UniversityOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT00962845 | Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | completed | Early Phase 1 | 20 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT03655756 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | completed | Early Phase 1 | 7 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT03526185 | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | terminated | Early Phase 1 | 6 | Yale UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT04223648 | Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma | withdrawn | Early Phase 1 | 0 | Yale UniversityOTHER | 0 | Nov 22, 2021 | clinicaltrials |
| NCT05009446 | Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM(SNMM) | unknown | Early Phase 1 | 28 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT04285749 | Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT03338777 | Suicide Plus Immune Gene Therapy for Advanced Melanoma(IGTM-101) | terminated | Early Phase 1 | 4 | Hospital Italiano de Buenos AiresOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03022565 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | withdrawn | Early Phase 1 | 0 | University of MiamiOTHER | 0 | Feb 6, 2020 | clinicaltrials |
| NCT02320305 | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | completed | Early Phase 1 | 23 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03649529 | Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy | unknown | Early Phase 1 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 6, 2019 | clinicaltrials |
| NCT02316795 | Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma | completed | Early Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01789827 | Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy | completed | Early Phase 1 | 5 | Mayo ClinicOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT01666353 | PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01748747 | Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery | completed | Early Phase 1 | 30 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01568996 | Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions | completed | Early Phase 1 | 17 | John KirkwoodOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00972933 | Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma | completed | Early Phase 1 | 59 | Diwakar DavarOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00871533 | Pilot Study of IFN α2b for Melanoma Patients | terminated | Early Phase 1 | 50 | University of PittsburghOTHER | 1 | Aug 4, 2017 | clinicaltrials |
| NCT01209676 | IMCgp100 in Advanced Unresectable Melanoma | completed | Early Phase 1 | 1 | University of PennsylvaniaOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01425749 | Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI(Mel55) | completed | Early Phase 1 | 25 | Craig L Slingluff, JrOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01730157 | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases | terminated | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02442466 | Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma | terminated | Early Phase 1 | 5 | MelCure SAINDUSTRY | 0 | May 20, 2015 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials